long intergenic non-protein coding RNA 2000Genealiases: []
Q-omics provides the consensus-scored LINC02000 profile across patient tissues and cancer cell-line models. LINC02000 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC02000 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, LINC02000 RNA expression shows 7,329 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, COAD, and ESCA as cancer lineages where LINC02000 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02000 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02000 survival associations across molecular data types. LINC02000 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02000 RNA expression–survival associations across cancer types. High LINC02000 expression shows unfavorable associations in MESO, LIHC and ESCA, but favorable associations in KIRC, UCS and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify MESO as the clearest survival context for LINC02000 RNA expression.
This table summarizes LINC02000 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02000. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02000 shows lower tumor expression in COAD, KICH and READ and higher tumor expression in KIRC, LUAD and ESCA. The COAD box plot shows higher LINC02000 RNA expression in normal versus tumor tissue (log2 FC = −1.777, t-test p < 0.001).
This table shows molecular features associated with LINC02000 in patient tissues and cancer cell lines. In patient samples, LINC02000 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
